Article Text

Download PDFPDF

2SPD-018 Impact of inhalers on CO2 emission in a health area
  1. A Luaces-Rodríguez,
  2. P Feijoo-Vilanova,
  3. L Caeiro-Martínez,
  4. E Gómez-Costa,
  5. A Martínez-Pradeda,
  6. S Rotea-Salvo,
  7. S Albiñana-Pérez,
  8. I Martín-Herranz
  1. A Coruña University Hospital Complex, Pharmacy, A Coruña, Spain


Background and Importance There are several types of devices for inhaled therapy, being the most used ones: pressurised metered-dose inhalers (pMDIs), dry-powder inhalers (DPIs) and soft mist inhalers (SMIs). All the types have some environmental impact due to their effect on CO2 emissions, although very low compared to total CO2 emissions, pMDIs have proven to exert higher CO2 emissions than DPIs and SMIs.

Aim and Objectives The main objective is to estimate the impact of pMDIs, DPIs and SMIs, prescribed for any indication, on CO2 emissions in our health care area during 1 year.

Material and Methods Number of inhalers consumed in our health care area with a population of 550086 inhabitants during 2022 was extracted from the Pharmacy Benefit Management Data.

The inhalers’ carbon footprint values were extracted from the publication Montoro et al. The estimated mean value of Kg CO2-eq/year/pack was 16.69 for pMDIs, 1.02 for DPIs and 0.59 for SMIs.

Results Of the total amount of inhalers consumed during 2022, 39.21% were pMDIs, 54.47% were DPIs and only 6.33% were SMIs.

Considering the estimated correction value, the carbon footprint was 2297846 kg CO2-eq for pMDIs (91.69% of the total carbon footprint of all the inhalers), 195104 kg CO2-eq for DPIs (7.79%) and 13105 kg CO2-eq for SMIs (0.52%).

Conclusion and Relevance The carbon footprint of the pMDIs represented more than 90% of the total carbon footprint of all the inhalers, even when consumption of pMDIs represented less than the 40%. This put in evidence the considerable higher environmental impact of pMDIs compared to DPIs.

However, this does not go in line with several societies and organisms which keep defending that efficacy, safety and patient suitability must continue to be the main factors when choosing a type of inhaler for each patient.

References and/or Acknowledgements 1. Montoro J, Antolín-Amérigo D, Izquierdo-Domínguez A, Zapata JJ, González G, Valero A. Impact of Asthma Inhalers on Global Climate: A Systematic Review of Their Carbon Footprint and Clinical Outcomes in Spain. J Investig Allergol Clin Immunol. 2023 Jul 27;33(4):250–262. doi: 10.18176/jiaci.0887. Epub 2023 Jan 4. PMID: 36648318.

The authors acknowledge the Pharmaceutical Benefit Management Service – SERGAS (Spain) for the data provided.

Conflict of Interest No conflict of interest.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.